The phase 3 clinical trial will cover around 28,500 subjects, aged 18 years and above, and it will be conducted in 21 sites across ten states, including Delhi, Mumbai, Patna and Lucknow.
The Hyderabad-based Bharat Biotech has fixed the price of its COVID-19 vaccine, Covaxin, at Rs 600 per dose for state governments and at Rs 1,200 per dose for private hospitals. The Pune-based Serum Institute of India, the world's largest vaccine maker in terms of volume, has announced a price of Rs 400 per dose for its COVID-19 vaccine, 'Covishield', for state governments and Rs 600 per dose for private hospitals.
Prime Minister Narendra Modi urged CEOs of US majors to take advantage of India's growth story as the country is making all efforts to become the third largest economy of the world in his third term. India is currently the fifth largest economy of the world after the US, China, Germany and Japan with a GDP of around $3.9 trillion. India has been the fastest growing large economies of the world with GDP growth rate of over 7 per cent for the last three consecutive years.
This will be an upfront payment for the vaccine doses that these two companies will supply to the government.
The first vaccine candidate will be an intra-muscular one, followed by intra-dermal and nasal ones, depending on test results.
Bharat Biotech applied to the Drugs Controller General of India (DCGI) seeking permission for conducting phase 1 and phase 2 clinical trials of the intranasal vaccine following which the subject expert committee of the CDSCO on Tuesday deliberated on the application and recommended granting permission for phase 1 trial.
Several states and UTs including Delhi, Maharashtra, Karnataka and Telangana have decided to opt for global tenders for procurement of anti-coronavirus shots with the domestic supply falling short to meet the rising demand.
Amid the reports of coronavirus vaccine shortage from various states, the central government and Hyderabad-based Bharat Biotech are willing to invite other companies which want to produce COVAXIN in a bid to scale up the vaccine production, said NITI Aayog member Dr VK Paul, on Thursday.
The vaccine candidate -- 'Covaxin' -- is being indigenously developed by the Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).
India has covered enough population with vaccine and infection, but protein vaccines should remain available on payment basis for elderly and those with comorbidities.
India's biotechnology industry is pushing the government for fiscal incentives, import duty exemption and correction of policy that gives MNCs higher drug prices than "desi" producers, ahead of the Union budget.
An industry-friendly regulatory mechanism for biotech sector would be put in place by November, Kapil Sibal, Union Minister for Science and Technology, said.
Serious AESI, which included stroke and Guillain-Barre syndrome, were reported in one per cent of individuals, the study, which looked at long-term safety of the BBV152 vaccine in adolescents and adults, claimed.
Take the Rediff Biz Quiz and find out how much you know about India and its biotech firms.
Bharat Biotech started work on developing a vaccine against Zika way back in 2014.
Panacea Biotech on Wednesday announced a collaboration with Netherlands Vaccine Institute for supply of bulk inactivated polio vaccines. \n
India's economic boom story does not just stop by the information technology sector.
The sector earns a little more than half of its revenue from exports.
Ramaswamy was a distant fourth with 7.7 per cent of the votes polled in the Iowa Caucus
The method of data collection has a high risk of bias, the ICMR DG said.
Indian-American multimillionaire biotech entrepreneur Vivek Ramaswamy's popularity rating and online fundraising have surged, a day after his impressive performance at the first Republican presidential primary debate.
Observing that India was on the "threshold of biotech revolution", International Finance Corporation, the private sector arm of the World Bank, has said the country was the "centrepiece" of its global strategy.
Biocon Ltd on Tuesday said it has earned the distinction of being the only Asian biopharma company to feature among the top biotechnology employers in the world as ranked by Science magazine.
British and Indian companies have inked three new tie-ups in the biotech sector, British High Commissioner to India Sir Michael Arthur said on Friday.
Department of Biotechnology offers post-graduate students the chance to train with the top Biotech companies in India.
'Sell in May, go away' is a popular market adage. But 'Don't sell any new shares in May' is the best kept secret of Dalal Street that's set to break. Sample this: the last four General Election election cycles starting 2004 have not seen a single initial public offering (IPO) launch during the month of May.
Explore, engage, participate and excel in as many co-curricular activities and hackathons as possible to improve your self-confidence, communication skills and overall personality, advises rediffGURU Chocko Valliappa.
Under the partnership, Bharat Biotech will use the patented virus like particle technology platform of Novavax to develop the single dosage pandemic influenza vaccine and undertake clinical trials before manufacturing and marketing the same.\n\n
Lupin Ltd, one of the top five domestic pharmaceutical companies, plans to revamp its drug research programme and foray into novel biotech and reverse engineering of biotech drugs (or biosimilars).
The manufacturing licence of Noida-based pharmaceutical firm Marion Biotech has been cancelled by the Uttar Pradesh authorities, according to officials.
A bill to establish a statutory independent regulator for biotech sector covering research, transport, import, manufacture and use of organisms and products of modern biotechnology was introduced in the Lok Sabha on Monday.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances